Cargando…
Theoretical Prediction of Dual-Potency Anti-Tumor Agents: Combination of Oxoplatin with Other FDA-Approved Oncology Drugs
Although Pt(II)-based drugs are widely used to treat cancer, very few molecules have been approved for routine use in chemotherapy due to their side-effects on healthy tissues. A new approach to reducing the toxicity of these drugs is generating a prodrug by increasing the oxidation state of the met...
Autor principal: | Cerón-Carrasco, José Pedro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369966/ https://www.ncbi.nlm.nih.gov/pubmed/32635199 http://dx.doi.org/10.3390/ijms21134741 |
Ejemplares similares
-
In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent
por: Olszewski, Ulrike, et al.
Publicado: (2009) -
Translatability of in vitro potency to clinical efficacious exposure: A retrospective analysis of FDA‐approved targeted small molecule oncology drugs
por: Kotani, Naoki, et al.
Publicado: (2023) -
Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
por: Jiang, Pengfei, et al.
Publicado: (2014) -
Correction: novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
por: Jiang, Pengfei, et al.
Publicado: (2014) -
In silico Selection and Experimental Validation of FDA-Approved Drugs as Anti-quorum Sensing Agents
por: Mellini, Marta, et al.
Publicado: (2019)